Sablerolles Roos S G, Hogenhuis Freija E F, Lafeber Melvin, van de Loo Bob P A, Borgsteede Sander D, Boersma Eric, Versmissen Jorie, van der Kuy Hugo M
Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Department of Hospital Pharmacy, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Eur J Hosp Pharm. 2020 Jul;27(4):191-193. doi: 10.1136/ejhpharm-2020-002329.
Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.
关于诸如血管紧张素转换酶抑制剂（ACE抑制剂）或血管紧张素II受体阻滞剂（ARB）等药物与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）以及新型冠状病毒肺炎（COVID-19）临床结局之间的各种理论，正在主流媒体和医学文献中流传。这些理论基于这样一个事实，即血管紧张素转换酶2（ACE2）通过病毒刺突蛋白与ACE2结合促进SARS-CoV-2细胞入侵。然而，ACE抑制剂、ARB和其他药物对ACE2的影响尚不清楚，所有理论都基于主要来自动物研究的相互矛盾的证据。因此，迫切需要临床证据。本研究的目的是调查这些药物的使用与COVID-19患者临床结局之间的关系。患者将来自欧洲的几家医院。数据将收集到外部服务器上一个用户友好型数据库（Digitalis）中。分析将针对性别、年龄以及心血管疾病、高血压和糖尿病的存在情况进行调整。这些结果将为COVID-19预防和治疗策略的随机对照试验提供更合理的选择依据。
